Polaryx Therapeutics (PLYX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs).

• Pipeline includes small molecule therapies (PLX-200, PLX-300, PLX-100) and a gene therapy candidate (PLX-400), targeting multiple LSDs with high unmet need.

• Lead candidate PLX-200 is an oral, repurposed drug advancing through a Phase 2 proof-of-concept basket trial (SOTERIA) for several LSDs, with trial initiation expected in the first half of 2026.

• Multi-modal approach aims to address both genetic and downstream pathological features of LSDs, leveraging mechanisms such as TFEB activation, lysosomal biogenesis, and neuroinflammation reduction.

• Business model includes leveraging regulatory designations (orphan drug, fast track, rare pediatric disease) and strategic partnerships for development and commercialization.

Financial performance and metrics

• No products approved for sale and no product revenue to date; operations funded primarily through equity issuances totaling $21.7 million since inception.

• Net loss of $30.4 million for the year ended December 31, 2024, and $7.5 million for the nine months ended September 30, 2025; accumulated deficit of $98.1 million as of September 30, 2025.

• Cash and cash equivalents of $5.7 million and working capital of $5.3 million as of September 30, 2025.

• Research and development expenses were $2.8 million in 2024 and $5.7 million for the nine months ended September 30, 2025; general and administrative expenses were $1.5 million in 2024 and $1.2 million for the nine months ended September 30, 2025.

• Substantial doubt exists about the ability to continue as a going concern beyond the third quarter of 2026 without additional capital.

Use of proceeds and capital allocation

• The direct listing is a resale by existing stockholders; the company will not receive any proceeds from the sale of shares by registered stockholders.

• All available funds and future earnings are intended to be retained to fund development, commercialization, and growth; no dividends anticipated in the foreseeable future.

• Future capital needs will be met through additional equity, debt financings, or strategic transactions as required.